Pierre Gravier's most recent trade in PTC Therapeutics Inc was a trade of 2,992 Common Stock done at an average price of $69.4 . Disclosure was reported to the exchange on Feb. 18, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 69.36 per share. | 18 Feb 2026 | 2,992 | 87,318 (0%) | 0% | 69.4 | 207,525 | Common Stock |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 76.95 per share. | 06 Jan 2026 | 2,139 | 90,310 (0%) | 0% | 76.9 | 164,596 | Common Stock |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 20,000 | 92,449 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 49.46 per share. | 15 Jul 2025 | 2,516 | 71,920 (0%) | 0% | 49.5 | 124,441 | Common Stock |
| Cassava Sciences Inc | Pierre Gravier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2025 | 26,500 | 26,500 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 50.10 per share. | 19 Feb 2025 | 1,168 | 75,603 (0%) | 0% | 50.1 | 58,512 | Common Stock |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 50.12 per share. | 19 Feb 2025 | 1,167 | 74,436 (0%) | 0% | 50.1 | 58,495 | Common Stock |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 56,250 | 56,250 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 22,500 | 76,771 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 34.02 per share. | 16 Jul 2024 | 2,269 | 53,531 (0%) | 0% | 34.0 | 77,200 | Common Stock |
| Cassava Sciences Inc | Pierre Gravier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Gravier Pierre | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 47,500 | 47,500 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 19,000 | 52,700 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 3,100 | 55,800 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Gravier Pierre | CHIEF FINANCIAL OFFICER | Purchase of securities on an exchange or from another person at price $ 25.81 per share. | 12 Dec 2023 | 7,700 | 33,700 (0%) | 0% | 25.8 | 198,736 | Common Stock |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2023 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2023 | 26,000 | 26,000 (0%) | 0% | 0 | Common Stock |